BRAF and breast carcinoma: In in vivo and xenograft models of a brain-tropic Her2-positive, BRAF-mutated breast cancer cell line, pazopanib prevented the growth of brain metastasis in association with reduced MAPK pathway activation but no change in markers of angiogenesis.